LONDON (Alliance News) - Liquid biopsy firm Angle PLC said it is making good progress on recruiting patients for its ANG-002 clinical study.
The study is focusing on a treatment for metastatic breast cancer, and Angle is looking to become the first company to get US Food & Drug Administration clearance for a platform which captures and harvests intact circulating tumour cells for analysis.
Angle has so far enrolled over 75% of the 400 people needed - half will be metastatic breast cancer patients, and the others healthy people of a similar age and demographic.
Angle hopes to have the study, and associated analysis, to be finished by the end of the first quarter of 2019.
Founder & Chief Executive Andrew Newland commented: "Our significant and sustained efforts to complete the clinical and analytical studies needed to support our FDA submission are progressing well."
"We believe there is a tremendous opportunity for Angle to secure the first ever FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis," he added.
"This would be a key step in establishing the Parsortix system as the system of choice for CTC liquid biopsy, securing a leading position in the emerging multi-billion dollar liquid biopsy market."
Shares were down 6.5% on Thursday at a price of 40.20 pence each.
Angle (AGL)